The MDS Foundation proudly partners with the following organizations
The MDS Foundation proudly partners with the following organizations
Phone within the US
1-(800)-637-0839Outside the US only
1-(609)-298-1035Address
The MDS Foundation
228 Park Ave S
PMB 118983
New York
NY 10003-1502
The MDS Foundation is a global nonprofit 501(c)(3) advocacy organization (EIN 22-3283911), supporting patients, families, and healthcare providers in the fields of MDS and related diseases for over 30 years.
© 2024 MDS Foundation. All rights reserved.
Every gift helps patients, caregivers, and healthcare professionals access life-saving resources, support, and education. Together, we can make a difference. Even a small contribution can create a big impact. Thank you for your generosity.
Latest News
Explore the forefront of MDS research, treatments, and community happenings to stay informed on the ever-evolving landscape of MDS care.
-800x533.jpg&w=3840&q=75)
June 19, 2025
ASCO 2025 Plain Language Summary – Dr. Goldberg Highlights New Research for MDS
Research is the pathway towards a cure for MDS. From May 30 to June 3, 2025, doctors from around the world met to talk about new treatments at the annual meeting of the American Society of Clinical Oncology (ASCO).
Dr. Goldberg has prepared an easy-to-understand summary of the key MDS studies presented.
June 18, 2025
Introducing JOE in AML: A New Era of Empowerment and Education for the AML Community
The MDS Foundation is proud to expand its Journey of Empowerment (JOE) initiative to the acute myeloid leukemia (AML) community - an interactive platform to support patients and caregivers with trusted information, engaging education, and tailored resources.
June 12, 2025
New results for Johnson & Johnson’s bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
Johnson & Johnson (NYSE:JNJ) today announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine (VEN + AZA) for the treatment of acute myeloid leukemia (AML) harboring KMT2A gene rearrangements (KMT2Ar) or NPM1 gene mutations (NPM1m). The study evaluated patients with newly diagnosed, intensive chemo-ineligible AML and relapsed or refractory AML.1 The results were featured in an oral presentation at the 2025 European Hematology Association (EHA) Congress ( S137).
May 30, 2025
Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology
Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announced the publication of the results of its Phase I BEXMAB study in the prestigious Lancet Haematology which reinforced the safety and efficacy of the treatment in patients with high-risk myelodysplastic syndrome (HR-MDS) and relapsed/refractory (r/r) acute myeloid leukemia (AML).
May 29, 2025
Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
Auron Therapeutics announced that the first patient has been dosed with AUTX-703 in a first-in-human, Phase 1 clinical trial for patients with advanced hematologic malignancies (NCT06846606).
May 28, 2025
Geron announced presentations at ASCO and EHA underscoring RYTELO® (imetelstat) efficacy and safety across range of LR-MDS patients; showcasing momentum of myelofibrosis program
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced presentations on RYTELO® (imetelstat) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress. Together, the presentations reinforce the potential benefits of the first-in-class oligonucleotide telomerase inhibitor RYTELO for a range of patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia and showcase the progress Geron is making with the ongoing IMpactMF and IMproveMF trials of imetelstat in myelofibrosis (MF).
May 28, 2025
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
Servier announced that the company was ranked among the top companies across several categories in PatientView's 2024 Corporate Reputation of Pharma in the U.S. survey. This annual survey captures insights from more than 350 patient organizations reflecting their firsthand experiences, perceptions and familiarity with pharmaceutical companies.
May 22, 2025
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
Rigel announced seven poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress. Presentations will include supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML.
